Ambrisentan, an endothelin receptor type A-selective endothelin receptor antagonist, for the treatment of pulmonary arterial hypertension

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 11, 2009, Pages 1847-1858

  Kingman, Martha ^a   Ruggiero, Rosechelle ^a   Torres, Fernando ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Ambrisentan; Endothelin receptor antagonist; Pulmonary arterial hypertension

Indexed keywords

AMBRISENTAN; BERAPROST; BOSENTAN; DIGOXIN; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; KETOCONAZOLE; PROSTACYCLIN; SILDENAFIL; SITAXSENTAN; TADALAFIL; UNIPROST;

ABDOMINAL PAIN; AREA UNDER THE CURVE; CATHETER INFECTION; CONSTIPATION; COUGHING; DIARRHEA; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DYSPEPSIA; DYSPNEA; EPISTAXIS; ERYTHEMA; FLUSHING; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEART PALPITATION; HUMAN; INJECTION SITE PAIN; INJECTION SITE REACTION; INSOMNIA; JAW PAIN; LIVER FUNCTION; LIVER FUNCTION TEST; MYALGIA; NAUSEA; NOSE CONGESTION; PAIN; PERIPHERAL EDEMA; PULMONARY HYPERTENSION; QUALITY OF LIFE; RASH; REVIEW; RHINOPHARYNGITIS; RISK; SIDE EFFECT; SINUSITIS; SURVIVAL; TRISMUS; VOMITING; WORLD HEALTH ORGANIZATION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; DRUG MONITORING; HUMANS; HYPERTENSION, PULMONARY; PHENYLPROPIONATES; PYRIDAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, ENDOTHELIN A; SURVIVAL RATE;

EID: 68149148794     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903061275     Document Type: Review

References (47)

1. Taichman DB, Mandel J. Epidemiology of pulmonary arterial hypertension. Clin Chest Med 2007;28(1):1-22, vii
2. D'alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115(5):343-349
3. Badesch DB, Abman SH, Ahearn GS, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126(Suppl 1):35S-62S
4. Badesch DB, Abman SH, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 2007;131(6):1917-1928 (Pubitemid 46981654)
5. Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003;41(12):2119-2125 (Pubitemid 36724255)
6. Pfizer I. Revatio® (sildenafil citrate) Tablets, 20 mg. United States Food and Drug Administration Drug Product Label. 2006
7. Galie N, Brundage BH, Ghofrani A, et al. Tadalafil therapy in pulmonary arterial hypertension: results of a randomized, double-blind, placebo-controlled, phase III study [abstract]. Eur Heart J 2008;29(Suppl):519
8. Kirkby NS, Hadoke PW, Bagnall AJ, et al. The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? Br J Pharmacol 2008;153(6):1105-1119
9. Stewart DJ, Levy RD, Cernacek P, et al. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 1991;114(6):464-469
10. Nootens M, Kaufmann E, Rector T, et al. Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels. J Am Coll Cardiol 1995;26(7):1581-1585
11. Actelion Pharmaceuticals Ltd. Tracleer (bosentan) tablets. United States Food and Drug Administration Drug Product Label. 2006
12. Greene S, Nunley K, Weber S, et al. ETA vs ETB receptor selectivity of endothelin-1 receptor antagonists in human myocardial membranes. J Am Coll Cardiol 2006;47(4 Suppl A):307A
13. Gilead Sciences I. Food and Drug Administration [Clinical Pharmacology & Biopharmaceutics Review (part 1)] for original New Drug Application 22-081 [online]. Available from: http://www.fda.gov/cder/foi/nda/2007/022081s000TOC. htm [Accessed 21 Oct 2008]
14. Gilead Sciences, Inc. Food and Drug Administration [Pharmacology Review (Part 1)] for original New Drug Application 22-081 [online]. Available from: http://www.fda.gov/cder/foi/nda/2007/022081s000TOC.htm [Accessed 21 Nov 2008]
15. Gilead Sciences. Letairis (ambrisentan) Package Insert. Foster City, CA. 2008
16. Galie N, Badesch D, Oudiz R, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005;46(3):529-535 (Pubitemid 41040298)
17. Leuchte HH, Holzapfel M, Baumgartner RA, et al. Characterization of brain natriuretic peptide in long-term follow-up of pulmonary arterial hypertension. Chest 2005;128(4):2368-2374 (Pubitemid 41507581)
18. Nagaya N, Nishikimi T, Uematsu M, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000;102(8):865-870 (Pubitemid 30671502)
19. Park MH, Scott RL, Uber PA, et al. Usefulness of B-type natriuretic peptide as a predictor of treatment outcome in pulmonary arterial hypertension. Congest Heart Fail 2004;10(5):221-225
20. Leuchte HH, Holzapfel M, Baumgartner RA, et al. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J Am Coll Cardiol 2004;43(5):764-770 (Pubitemid 38296473)
21. Galie N. Ambrisentan decreases BNP in patients with PAH and improvements in BNP were associated with improvements in 6MWD and who functional class. Chest 2007;132(4 Suppl S):632S
22. Gilead Sciences, Inc. Food and Drug Administration [Clinical Pharmacology & Biopharmaceutics Review (Part 2)] for original New Drug Application 22-081 [online]. Available from: http://www.fda.gov/cder/foi/nda/2007/ 022081s000TOC. htm [Accessed 21 Nov 2008]
23. Burgess G, Hoogkamer H, Collings L, et al. Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. Eur J Clin Pharmacol2008;64(1):43-50
24. Coyne TC, Garces PC, Kramer W. No Clinical Interaction between Sitaxsentan and Sildenafil. Annals of the Rheumatic Diseases 2005; 64 (Suppl. 3).
25. Wrishko RE, Dingemanse J, Yu A, et al. Pharmacokinetic Interaction Between Tadalafil and Bosentan in Healthy Male Subjects. J Clin Pharmacol 2008;48(5):640-1618
26. Horn EM, Widlitz AC, Barst RJ. Sitaxsentan, a selective endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension.
27. Brouwer KR, Wille KR, Gorczynski RJ. Ambrisentan, darusentan, bosentan, and sitaxsentan: differences in inhibition of hepatobilliary transporters in two species. Drug Metabolism Rev 2007:A296
28. Spence R, Mandagere A, Dufton C, et al. Pharmacokinetics and safety of ambrisentan in combination with sildenafil in healthy volunteers. J Clin Pharmacol 2008;48(12):1451-1459
29. Spence R, Harrison B, Mandagere A, et al. No clinical relevant pharmacokinetic interaction between ambrisentan and tadalafil. J Pharm Sci [serial online] March 18, 2009
30. Walker G, Mandagere A, Dufton C, et al. The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers. Br J Clin Pharmacol 2009;67(5):527-534
31. Galie N, Olschewski H, Oudiz R, et al. Ambrisentan for the treatment of pulmonary arterial hypertension. Results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) Study 1 and 2. Circulation 2008;117(23):3010-3019
32. Richards D, Walker G, Mandagere A, et al. Effect of ketoconazole on the pharmacokinetic profile of ambrisentan. J Clin Pharmacol 2009;49:719-724
33. Richards D, Spence R, Mandagere A, et al. The effects of ambrisentan on the pharmacokinetics of a single dose of digoxin. British Pharmacological Society Winter Meeting. Brighton 2008 CPO25. (online publication http://bps.conference-services.net/viewPDF. asp?conferenceID = 1472& abstractID = 269328)
34. Olschewski H, Galie N, Ghofrani HA, et al.; and the Aries-2 Study Group. Ambrisentan improves exercise capacity and time to clinical worsening in patients with pulmonary arterial hypertension: results of the ARIES-2 study [abstract]. Am Thorac Soc 2006;3:A728
35. Gilead Sciences, Inc. Food And Drug Administration [Medical Review (Part 1)] for original New Drug Application 22-081 [online]. Available from: http://www.fda.gov/cder/foi/nda/2007/022081s000TOC. htm [Accessed 21 Oct 2008]
36. Badesch D, Aries Study Group. Ambrisentan therapy for pulmonary arterial hypertension: a comparison by path etiology. Chest 2007;132(4 Suppl S):488S-9S
37. Olschewski H, Galie N, Rubin LJ, Aries Study Group. Ambrisentan improves exercise capacity and dyspnea in WHO functional Class II and Class III patients with pulmonary arterial hypertension. Am Thorac Soc 2007;175:A1001
38. Oudiz R, Aries Study Group. Long-term ambrisentan therapy provides sustained benefit in patients with pulmonary arterial hypertension. Chest 2007;132(4 Suppl S):474S
39. Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;169(4):441-447 (Pubitemid 38187114)
40. Galie N, Olschewski H, Rubin L, Aries Study Group. Ambrisentan therapy for pulmonary arterial hypertension: an integrated analysis of the ARIES-1 and ARIES-2 studies. Am Thorac Soc 2007;175:A397
41. Cheng JW. Ambrisentan for the management of pulmonary arterial hypertension. Clin Ther 2008;30(5):825-833 (Pubitemid 351802283)
42. Barst RJ, Langleben D, Badesch D, et al. Treatment of pulmonary arterial hypertension with the selective endothelin-a receptor antagonist sitaxsentan. J Am Coll Cardiol 2006;47(10):2049-2056
43. Benza RL, Barst RJ, Galie N, et al. Sitaxsentan for the treatment of pulmonary arterial hypertension: a one year, prospective, open label, observation of outcome and survival. Chest 2008
44. McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005;25:244-249 (Pubitemid 40246523)
45. McGoon MD, Frost AE, Oudiz RJ, et al. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities [online]. Chest 2008;135(1):122-129
46. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358(9288):1119-1123 (Pubitemid 32971843)
47. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346(12):896-903 (Pubitemid 34984638)